GlassScriptPhysician profile
Christopher Brian Gong
NPI 1558991158
$4,364.15
in general payments reported to CMS, 2019-2025
29 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $449 · 2022: $837 · 2023: $1,065 · 2024: $927 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,077.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $762.80 | 2021-2025 | |
| Pfizer INC. | $718.28 | 2022-2025 | |
| Novo Nordisk INC | $679.14 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $436.36 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $210.93 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.07 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $157.02 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $149.60 | 2021-2025 | Repatha, Otezla, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.94 | 2021-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $96.28 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.85 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.50 | 2021-2025 | Jardiance |
| Dexcom, INC. | $87.09 | 2021-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $84.43 | 2024-2025 | Auvelity |
| Sumitomo Pharma America, INC. | $74.00 | 2023-2025 | Gemtesa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $67.72 | 2021-2024 | Farxiga, Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $57.31 | 2022 | |
| Merck Sharp & Dohme LLC | $50.35 | 2022-2025 | Capvaxive, Gardasil 9, Gardasil |
| Phathom Pharmaceuticals, INC. | $44.75 | 2024-2025 | Voquezna |
| Seqirus USA INC | $38.92 | 2024 | Fluad, Flucelvax |
| Corcept Therapeutics | $35.95 | 2025 | Korlym |
| Exact Sciences Corporation | $33.35 | 2025 | The Cologuard Plus Collection Kit |
| Sunovion Pharmaceuticals INC. | $32.22 | 2022 | |
| Philips North America LLC | $20.13 | 2024 | (Ck7) Extended Holter |
| Teleflex LLC | $15.96 | 2021 | |
| Medtronic, INC. | $14.61 | 2024 | Intellis Adaptivestim |
| Intra-Sana Laboratories | $13.17 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Biohaven Pharmaceuticals, INC. | $13.12 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Gong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.